Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Chemotherapy

Bringing atoms to bedside with targeted alpha therapy

Nature Reviews Chemistry volume 10, pages 7–8 (2026)Cite this article

Subjects

Targeted alpha therapy (TAT) is a growing field in medicinal chemistry owing to the ability of alpha particles to selectively deliver radiation to tumour cells. In the past year, these research efforts have resulted in clinical trials in TAT using 225Ac, 212Pb, 223Ra, and 211At as alpha emitters.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic representation of the administration of a radiopharmaceutical employed for the clinical trial of TAT.

References

  1. Filosofov, D., Baimukhanova, A., Khushvaktov, J., Kurakina, E. & Radchenko, V. Potent candidates for targeted alpha therapy (TAT). Nucl. Med. Biol. 146–147, 109027 (2025).

    Article  PubMed  Google Scholar 

  2. Almasi, S. et al. Combinatorial effect of the PSMA targeted alpha therapeutic, [225Ac]-FPI-2265, and olaparib in a pre-clinical prostate cancer tumor model. J. Nucl. Med. 65, 241556 (2024).

    Google Scholar 

  3. Saboury, B. et al. Abstract CT107: A phase 1a/b, open-label, dose-escalation study of 225Ac-ABD147 for locally advanced or metastatic small cell lung cancer and large cell neuroendocrine carcinoma of the lung following platinum-based chemotherapy. Cancer Res. 85, CT107 (2025).

    Article  Google Scholar 

  4. Tombal, B. et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 36, 1058–1067 (2025).

    Article  CAS  Google Scholar 

  5. Saidi, A. et al. Side-by-side comparison of the in vivo performance of [212Pb]Pb-DOTAMTATE and other SSTR2-targeting compounds. J. Nucl. Med. 66, 391–397 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Watabe, T. et al. Phase I investigator-initiated clinical trial of targeted alpha therapy using [At]NaAt for refractory thyroid cancer (Alpha-T1 trial). J. Nucl. Med. 66, 251278 (2025).

    Google Scholar 

  7. Joho, T. et al. Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma. Ann. Nucl. Med. 39, 994–1013 (2025).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the support of the Department of Energy, Office of Science, Office of Basic Energy Sciences, Chemical Sciences, Geosciences, and Biosciences Division, Heavy Element Chemistry Program at the Lawrence Berkeley National Laboratory (LBNL) under contract DE-AC02-05CH11231.

Author information

Authors and Affiliations

  1. Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

    Abhyavartin Selvam & Brooklyn D. Green

  2. Department of Chemistry, University of California, Berkeley, CA, USA

    Abhyavartin Selvam & Brooklyn D. Green

Authors
  1. Abhyavartin Selvam
    View author publications

    Search author on:PubMed Google Scholar

  2. Brooklyn D. Green
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Abhyavartin Selvam or Brooklyn D. Green.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Selvam, A., Green, B.D. Bringing atoms to bedside with targeted alpha therapy. Nat Rev Chem 10, 7–8 (2026). https://doi.org/10.1038/s41570-025-00782-8

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41570-025-00782-8

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research